Gastric/Gastroesophageal Junction Adenocarcinoma Clinical Trials

3 recruiting

Gastric/Gastroesophageal Junction Adenocarcinoma Trials at a Glance

5 actively recruiting trials for gastric/gastroesophageal junction adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Jinan, Beijing, and Blacktown. Lead sponsors running gastric/gastroesophageal junction adenocarcinoma studies include Shandong Provincial Hospital, Bristol-Myers Squibb, and Henan Cancer Hospital.

Browse gastric/gastroesophageal junction adenocarcinoma trials by phase

Treatments under study

About Gastric/Gastroesophageal Junction Adenocarcinoma Clinical Trials

Looking for clinical trials for Gastric/Gastroesophageal Junction Adenocarcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric/Gastroesophageal Junction Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric/Gastroesophageal Junction Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 2

A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital96 enrolled1 locationNCT06829797
Recruiting
Phase 2

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital32 enrolled1 locationNCT06766578
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Phase 2

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Gastric/Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital69 enrolled1 locationNCT06774222
Recruiting
Phase 2

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT06415669